Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 07209960

Drug Profile

PF 07209960

Alternative Names: PF-07209960

Latest Information Update: 31 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Interleukin 15 replacements; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 20 Jul 2023 Pfizer terminates a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy and greater) in US (Unspecified route) due to pause in the development of PF 07209960 based on internal business decision (NCT04628780) (EudraCT2021-004587-10)
  • 26 May 2023 Pfizer completes a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy and greater) in US (Unspecified route) (NCT04628780)
  • 02 May 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (Pfizer pipeline, August 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top